Abstract:The search for new metal-based anticancer drug candidates is a fundamental task in medicinal inorganic chemistry. In this work, we assessed the potential of two new Ru( II )–phosphine–mercapto complexes as potential anticancer agents. The complexes, with the formula [Ru(bipy)(dppen)(Lx)]PF 6 [( 1 ), HL1 = 2-mercapto–pyridine and ( 2 ), HL2 = 2-mercapto–pyrimidine, bipy = 2,2′-bipyridine, dppen = cis -1,2-bis(diphenylphosphino)-ethylene] were synthesized and characterized by nuclear magnetic resonance (NMR) [ 1 H, 31 P( 1 H), and 13 C], high resolution mass spectrometry (HR-MS), cyclic voltammetry, infrared and UV-Vis spectroscopies. Complex 2 was obtained as a mixture of two isomers, 2a and 2b , respectively. The composition of these metal complexes was confirmed by elemental analysis and liquid chromatography-mass spectrometry (LC-MS). To obtain insights into their lipophilicity, their distribution coefficients between n -octanol/PBS were determined. Both complexes showed affinity mainly for the organic phase, presenting positive log P values. Also, their stability was confirmed over 48 h in different media ( i.e. , DMSO, PBS and cell culture medium) via HPLC, UV-Vis and 31 P{ 1 H} NMR spectroscopies. Since enzymes from the P-450 system play a crucial role in cellular detoxification and metabolism, the microsomal stability of 1 , which was found to be the most interesting compound of this study, was investigated using human microsomes to verify its potential oxidation in the liver. The analyses by LC-MS and ESI-MS reveal three main metabolites, obtained by oxidation in the dppen and bipy moieties. Moreover, 1 was able to interact with human serum albumin (HSA). The cytotoxicity of the metal complexes was tested in different cancerous and non-cancerous cell lines. Complex 1 was found to be more selective than cisplatin against MDA-MB-231 breast cancer cells when compared to MCF-10A non-cancerous cells. In addition, complex 1 affects cell morphology and migration, and inhibits colony formation in MDA-MB-231 cells, making it a promising cytotoxic agent against breast cancer.

Polymeric micelle-mediated delivery of half-sandwich ruthenium(II) complexes with phosphanes derived from fluoroloquinolones for lung adenocarcinoma treatment

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Polyphosphoester-stabilized cubosomes encapsulating a Ru(II) complex for the photodynamic treatment of lung adenocarcinoma

Half‐sandwich Ruthenium (II) Complexes with Triphenylamine Modified Dipyridine Skeleton and Application in Biology/luminescence Imaging

Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles.

Highly Potent Half- Sandwich Iridium and Ruthenium Complexes As Lysosome- Targeted Imaging and Anticancer Agents

Dual Functional Half-Sandwich Ru(II) Complexes: Lysosome-Targeting Probes and Anticancer Agents

New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

Anticancer Activity and Mechanism of Bis-Pyrimidine Based Dimetallic Ru(II)(η6-p-cymene) Complex in Human Non-Small Cell Lung Cancer Via P53-Dependent Pathway.

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Synthesis, Characterization and Anticancer Mechanism Studies of Fluorinated Cyclometalated Ruthenium(ii) Complexes

Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation

Potent Half-Sandwich Ru(Ⅱ) N^N (Aryl-Bian) Complexes: Lysosome-mediated Apoptosis, in Vitro and in Vivo Anticancer Activities

Potent half-sandwich Ru(II) N^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities

16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes As Lysosome-Targeted Anticancer Agents

New Nanostructured Materials Based on Mesoporous Silica Loaded with Ru(II)/Ru(III) Complexes with Anticancer and Antimicrobial Properties

Mitochondria-targeted half-sandwich rutheniumII diimine complexes: anticancer and antimetastasis via ROS-mediated signalling

A Liposome Encapsulated Ruthenium Polypyridine Complex As a Theranostic Platform for Triple-Negative Breast Cancer.

Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes

Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest